Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2016 · 10-Q
Revenue$601.00K$601.00K−85.0% vs Q1 2015 Net Income-$3.26M-$3.26MN/M vs Q1 2015 EPS Diluted-$0.23-$0.23N/M vs Q1 2015 Operating Income-$5,658,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,027,000N/M Margins · derivedOperating margin-941.4%−788.4 pt vs Q1 2015
Net margin-542.9%−314.6 pt vs Q1 2015
ended Mar 31, 2016 · filed May 10, 2016 · 40 d after period end